PT  - JOURNAL ARTICLE
ED  - ,
TI  - Risk of serious adverse effects with Janus kinase inhibitors
AID  - 10.1136/dtb.2022.000078
DP  - 2023 Jan 10
TA  - Drug and Therapeutics Bulletin
PG  - dtb-2022-000078
4099  - http://dtb.bmj.com/content/early/2023/01/09/dtb.2022.000078.short
4100  - http://dtb.bmj.com/content/early/2023/01/09/dtb.2022.000078.full
AB  - Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.